Basic Information

Gene symbol CD33 Synonyms CD33rSiglec, SIGLEC-3, SIGLEC3, p67 Type of gene protein-coding
Gene perturbation-related omics dataset PerturbAtlas
Description CD33 molecule

GTO ID GTC0488
Trial ID NCT03971799
Disease Acute Myeloid Leukemia
Altered gene CD33
Therapeutic/Target gene Target gene
TherapyCAR-T cell
Treatment CD33 CAR-T cells
PhasePhase1|Phase2
Recruitment statusRecruiting
TitleStudy of Anti-CD33 Chimeric Antigen Receptor-Expressing T Cells (CD33CART) in Children and Young Adults With Relapsed/Refractory Acute Myeloid Leukemia
Year2020
CountryUnited States
Company sponsorCenter for International Blood and Marrow Transplant Research
Other ID(s)17-CD33CART
Vector information
Vectorlentivirus

Clinical Result

Cohort1: dose level 1
Administration route None
Dosage 3E5 cells/kg
Donor type Autologous|Allogeneic
Pts 3
Age Child, Adult
Lymph depletion Yes
Outcome 0/3(CR).No Dose-limiting toxicities
Adverse reactions 0/3(≥Grade 3 CRS)
References DOI: 10.1182/blood-2023-179667
Cohort2: dose level 2
Administration route None
Dosage 1E6 cells/kg
Donor type Autologous|Allogeneic
Pts 3
Age Child, Adult
Lymph depletion Yes
Outcome 0/3(CR).No Dose-limiting toxicities
Adverse reactions 1/3(≥Grade 3 CRS)
References DOI: 10.1182/blood-2023-179667
Cohort3: dose level 3
Administration route None
Dosage 3E6 cells/kg
Donor type Autologous|Allogeneic
Pts 7
Age Child, Adult
Lymph depletion Yes
Outcome 0/7(CR).1 subject experienced DLT (grade 4 CRS)
Adverse reactions 2/7(≥Grade 3 CRS)
References DOI: 10.1182/blood-2023-179667
Cohort4: dose level 4
Administration route None
Dosage 1E7 cells/kg
Donor type Autologous|Allogeneic
Pts 6
Age Child, Adult
Lymph depletion Yes
Outcome 2/6(CR).1 subject experienced a prolonged grade 3 CRS (> 72 hours) and grade 3 ICANS, both constituting DLT and necessitating expansion of the cohort without additional DLTs seen.
Adverse reactions 1/6(≥Grade 3 CRS)
References DOI: 10.1182/blood-2023-179667

Relationship Graph

Overview of Knowledge Graph